High dose pharmaceutical grade biotin, MD1003, treatment preserves motor performance in a model of progressive neurodegeneration

被引：0
|
作者：
Nessler, S. [1 ]
Winkler, A. [1 ]
van der Meer, F. [1 ]
Gargareta, S. [1 ]
Cobos, A. [1 ]
Stadelmann, C. [1 ]
Nave, K. A. [2 ]
Brueck, W. [1 ]
机构：
[1] Univ Med Gottingen, Inst Neuropathol, Gottingen, Germany
[2] Max Planck Inst Expt Med, Dept Neurogenet, Gottingen, Germany
来源：
MULTIPLE SCLEROSIS JOURNAL | 2019年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P638
引用
收藏
页码：311 / 311
页数：1
相关论文
共 47 条
  • [1] Treatment of progressive MS with MD1003 (high dose pharmaceutical grade biotin): real-world evidence
    Ciron, J.
    Pignolet, B.
    Bucciarelli, F.
    Biotti, D.
    Lerebours, F.
    Dorcet, G.
    Rabadeux, C.
    Freitas, N.
    Bonneville, F.
    Brassat, D.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 693 - 693
  • [2] Real-world effectiveness of MD1003 (high dose pharmaceutical grade biotin) in patients with progressive MS
    Faure, J.
    Jauffret, J.
    Carreau, C.
    Legrain, P.
    Castex, C.
    Tourbah, A.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 281 - 282
  • [3] Biomarkers of treatment response in patients with progressive multiple sclerosis treated with high-dose pharmaceutical-grade biotin (MD1003)
    Collongues, Nicolas
    Kuhle, Jens
    Tsagkas, Charidimos
    Lamy, Julien
    Meyer, Nicolas
    Barro, Christian
    Parmar, Katrin
    Amann, Michael
    Wuerfel, Jens
    Kappos, Ludwig
    Moreau, Thibault
    Seze, Jerome
    [J]. BRAIN AND BEHAVIOR, 2021, 11 (02):
  • [4] High dose pharmaceutical grade biotin (MD1003) protects axons in a TMEV-induced mouse model of progressive multiple sclerosis
    Warrington, A.
    Perdomini, M.
    Bernard, D.
    Rodriguez, M.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 532 - 533
  • [5] High dose pharmaceutical grade biotin (MD1003) has no effect in a mouse model of experimental autoimmune encephalomyelitis
    Fournier, A. P.
    Macrez, R.
    Vivien, D.
    Bernard, D.
    Docagne, F.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 757 - 757
  • [6] Results of the Phase 3 SPI2 Study of MD1003 (high dose Pharmaceutical grade Biotin) in Progressive MS
    Cree, Bruce A. C.
    Cutter, Gary
    Wolinsky, Jerry S.
    Freedman, Mark S.
    Comi, Giancarlo
    Giovannoni, Gavin
    Hartung, Hans-Peter
    Sedel, Frederic
    Lublin, Fred
    [J]. NEUROLOGY, 2020, 94 (15)
  • [7] Immunomodulation associated with clinical and MRI worsening in patients with progressive MS treated with MD1003 (high dose pharmaceutical grade biotin)
    Pignolet, B.
    Ciron, J.
    Bucciarelli, F.
    Scandella, L.
    Biotti, D.
    Lerebours, F.
    Dorcet, G.
    Rabadeux, C.
    Freitas, N.
    Bonneville, F.
    Brassat, D.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 467 - 468
  • [8] Effect of MD1003 (high dose Pharmaceutical grade Biotin) in the Treatment of Progressive MS: Earlier Treatment Results in Lower Disability Over 48 Months
    De Seze, Jerome
    Edan, Gilles
    Moreau, Thibault
    Brochet, Bruno
    Sedel, Frederic
    Tourbah, Ayman
    [J]. NEUROLOGY, 2019, 92 (15)
  • [9] High-dose pharmaceutical grade biotin (MD1003) in amyotrophic lateral sclerosis: A pilot study
    Juntas-Morales, Raul
    Pageot, Nicolas
    Bendarraz, Abdelkarim
    Alphandery, Sebastien
    Sedel, Frederic
    Seigle, Stephanie
    Camu, William
    [J]. ECLINICALMEDICINE, 2020, 19
  • [10] Effect of MD1003 (high dose pharmaceutical grade biotin) for the treatment of progressive MS: 48-month follow-up data
    De Seze, J.
    Edan, G.
    Moreau, T.
    Brochet, B.
    Sedel, F.
    Tourbah, A.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 287 - 288
12345